CR10479A - Modulares bencimidazolicos de vr1 - Google Patents

Modulares bencimidazolicos de vr1

Info

Publication number
CR10479A
CR10479A CR10479A CR10479A CR10479A CR 10479 A CR10479 A CR 10479A CR 10479 A CR10479 A CR 10479A CR 10479 A CR10479 A CR 10479A CR 10479 A CR10479 A CR 10479A
Authority
CR
Costa Rica
Prior art keywords
bencimidazolic
modulars
compounds
formula
treatment
Prior art date
Application number
CR10479A
Other languages
English (en)
Inventor
R Player Mark
L Dax Scott
H Parsons William
Brandt Michael
R Calvo Raul
Patel Sharmila
Liu Jian
S Cheung Wing
C Jetter Michele
Lee Yu-Kai
A Youngman Mark
Pan Wenxi
M Wells Kenneth
A Beauchamp Derek
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR10479A publication Critical patent/CR10479A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La invencion se refiere a compuestos de Formula (I): a composiciones farmaceuticas que contienen tales compuestos y a metodos de tratamiento para utilizarlos.
CR10479A 2006-05-03 2008-12-03 Modulares bencimidazolicos de vr1 CR10479A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79750406P 2006-05-03 2006-05-03

Publications (1)

Publication Number Publication Date
CR10479A true CR10479A (es) 2009-03-31

Family

ID=38566108

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10479A CR10479A (es) 2006-05-03 2008-12-03 Modulares bencimidazolicos de vr1

Country Status (37)

Country Link
US (3) US7951829B2 (es)
EP (1) EP2021330B1 (es)
JP (1) JP5302884B2 (es)
KR (1) KR101434883B1 (es)
CN (1) CN101511797B (es)
AR (1) AR060840A1 (es)
AT (1) ATE482201T1 (es)
AU (1) AU2007248341C1 (es)
BR (1) BRPI0709803B8 (es)
CA (1) CA2651128C (es)
CO (1) CO6160329A2 (es)
CR (1) CR10479A (es)
CY (1) CY1111269T1 (es)
DE (1) DE602007009378D1 (es)
DK (1) DK2021330T3 (es)
EA (1) EA019386B1 (es)
EC (1) ECSP088854A (es)
ES (1) ES2350959T3 (es)
HK (1) HK1131971A1 (es)
HR (1) HRP20100700T1 (es)
IL (1) IL194916A (es)
JO (1) JO3602B1 (es)
MX (1) MX2008014108A (es)
MY (1) MY154595A (es)
NI (1) NI200800290A (es)
NO (1) NO341965B1 (es)
NZ (1) NZ572251A (es)
PE (1) PE20080065A1 (es)
PL (1) PL2021330T3 (es)
PT (1) PT2021330E (es)
RS (1) RS51473B (es)
SI (1) SI2021330T1 (es)
TW (1) TWI419882B (es)
UA (1) UA94749C2 (es)
UY (1) UY30322A1 (es)
WO (1) WO2007130780A2 (es)
ZA (1) ZA200810234B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076752A1 (en) * 2006-12-15 2008-06-26 Janssen Pharmaceutica N.V. Benzimidazole trpv1 inhibitors
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
TW200942549A (en) * 2007-12-17 2009-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
US20090156598A1 (en) * 2007-12-17 2009-06-18 Lebsack Alec D Imidazolopyrimidine modulators of TRPV1
CN101983197B (zh) * 2008-04-18 2015-04-22 大熊制药株式会社 新型苯并噁嗪苯并咪唑衍生物、含有该衍生物的药物组合物及其用途
US8232409B2 (en) 2008-10-15 2012-07-31 Janssen Pharmaceutica N.V. Heterocyclic benzimidazoles as TRPM8 modulators
US8217060B2 (en) 2009-05-15 2012-07-10 Janssen Pharmaceutica, Nv Benzimidazole derivatives useful as TRP M8 receptor modulators
US8323805B2 (en) * 2009-06-04 2012-12-04 Nitto Denko Corporation Emissive aryl-heteroaryl acetylenes
CN102002010A (zh) * 2009-08-31 2011-04-06 住友化学株式会社 双噁唑啉基烷烃化合物的精制方法
DK2709619T3 (en) 2011-05-16 2018-01-15 Cellceutix Corp RELATIONSHIPS FOR USING THE TREATMENT OF MUCOSITIS
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
EP2970269B1 (en) 2013-03-14 2017-04-19 Novartis AG 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
WO2015006520A1 (en) * 2013-07-11 2015-01-15 Bristol-Myers Squibb Company Ido inhibitors
JP2016535042A (ja) 2013-10-30 2016-11-10 ノバルティス アーゲー ２−ベンジル−ベンゾイミダゾール補体因子ｂ阻害剤およびその使用
WO2017043342A1 (ja) * 2015-09-08 2017-03-16 住友化学株式会社 トリアゾール化合物の製造方法
US10870630B2 (en) 2016-11-01 2020-12-22 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
ES2949366T3 (es) * 2018-05-03 2023-09-28 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivados de bencimidazol como moduladores del receptor huérfano gamma relacionado con retinoides (rory) y usos farmacéuticos de los mismos
CN108997398B (zh) * 2018-07-23 2020-12-15 被忽略疾病药物研发组织 一种3,3-二甲基苯并[c][1,2]氧杂戊硼烷-1(3h)-醇的制备方法
CN112745268B (zh) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并咪唑衍生物的晶型及制备方法
EP4053109A4 (en) * 2019-10-31 2022-12-21 Jiangsu Hengrui Medicine Co., Ltd. ACID ADDITION SALT BY RORy REGLER
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US6299796B1 (en) 1997-12-18 2001-10-09 Fuji Photo Film Co., Ltd. Styryl compound, method for the preparation thereof and electroluminescent element employing the same
US6748803B1 (en) * 2000-02-22 2004-06-15 Simmonds Precison Products, Inc. Liquid measurement system and shared interface apparatus for use therein
JP2006505570A (ja) * 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
TW200418806A (en) 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
RU2373204C2 (ru) * 2003-07-28 2009-11-20 Янссен Фармацевтика Н.В. Бензимидазольные, бензтиазольные и бензоксазольные производные и их применение в качестве модуляторов lta4h
NZ547109A (en) * 2003-10-28 2010-03-26 Vertex Pharma Benzimidazoles useful as modulators of ion channels
WO2006058338A2 (en) * 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
JP5345528B2 (ja) * 2006-07-04 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換複素環基を持つベンゾイミダゾール系カンナビノイド作動薬
WO2008076752A1 (en) * 2006-12-15 2008-06-26 Janssen Pharmaceutica N.V. Benzimidazole trpv1 inhibitors

Also Published As

Publication number Publication date
WO2007130780A2 (en) 2007-11-15
HK1131971A1 (en) 2010-02-12
ZA200810234B (en) 2010-02-24
MX2008014108A (es) 2008-11-14
IL194916A (en) 2013-01-31
US7951829B2 (en) 2011-05-31
US20110190344A1 (en) 2011-08-04
KR101434883B1 (ko) 2014-08-27
EA200870497A1 (ru) 2009-06-30
TWI419882B (zh) 2013-12-21
CO6160329A2 (es) 2010-05-20
NZ572251A (en) 2010-08-27
TW200808738A (en) 2008-02-16
US20110190364A1 (en) 2011-08-04
US20070259936A1 (en) 2007-11-08
AU2007248341C1 (en) 2013-01-17
PL2021330T3 (pl) 2011-03-31
ECSP088854A (es) 2008-11-27
DE602007009378D1 (de) 2010-11-04
HRP20100700T1 (hr) 2011-02-28
WO2007130780A3 (en) 2008-02-14
AR060840A1 (es) 2008-07-16
CY1111269T1 (el) 2015-08-05
JP5302884B2 (ja) 2013-10-02
PT2021330E (pt) 2010-12-03
NO20085031L (no) 2009-01-06
MY154595A (en) 2015-06-30
NO341965B1 (no) 2018-03-05
CN101511797B (zh) 2013-01-02
IL194916A0 (en) 2009-08-03
JO3602B1 (ar) 2020-07-05
CN101511797A (zh) 2009-08-19
BRPI0709803B1 (pt) 2019-12-10
JP2009535414A (ja) 2009-10-01
PE20080065A1 (es) 2008-02-25
UY30322A1 (es) 2007-08-31
BRPI0709803B8 (pt) 2021-05-25
DK2021330T3 (da) 2010-12-06
SI2021330T1 (sl) 2011-01-31
BRPI0709803A2 (pt) 2011-07-26
EP2021330B1 (en) 2010-09-22
AU2007248341A1 (en) 2007-11-15
EA019386B1 (ru) 2014-03-31
KR20090008428A (ko) 2009-01-21
AU2007248341B2 (en) 2011-12-08
ATE482201T1 (de) 2010-10-15
EP2021330A2 (en) 2009-02-11
NI200800290A (es) 2012-01-30
RS51473B (en) 2011-04-30
UA94749C2 (en) 2011-06-10
ES2350959T3 (es) 2011-01-28
CA2651128C (en) 2014-09-02
CA2651128A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
CR10479A (es) Modulares bencimidazolicos de vr1
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201100037A1 (ru) Органические соединения
UY30787A1 (es) "inhibidores benzoimidazolicos de trpv1"
GT200900027A (es) Compuestos organicos
GT200600117A (es) Nuevos compuestos farmaceuticos
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
UY31065A1 (es) Heterociclos ciclicos
TW200745122A (en) New compounds I
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
TW200738627A (en) Trialkylsilyl-indoles
SG158091A1 (en) Imidazoazepinone compounds
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
EA201000703A1 (ru) Производные пиразола в качестве ингибиторов 5-lo
UY29817A1 (es) Nuevos compuestos de azetidina, composiciones farmacéuticas que los contienen, procesos de preparación y uso terapéutico de los mismos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)